BR112022022527A2 - Compostos de metiltionínio para uso no tratamento de covid-19 - Google Patents

Compostos de metiltionínio para uso no tratamento de covid-19

Info

Publication number
BR112022022527A2
BR112022022527A2 BR112022022527A BR112022022527A BR112022022527A2 BR 112022022527 A2 BR112022022527 A2 BR 112022022527A2 BR 112022022527 A BR112022022527 A BR 112022022527A BR 112022022527 A BR112022022527 A BR 112022022527A BR 112022022527 A2 BR112022022527 A2 BR 112022022527A2
Authority
BR
Brazil
Prior art keywords
compounds
covid
methylthionium
treatment
methylthioninium
Prior art date
Application number
BR112022022527A
Other languages
English (en)
Inventor
Arastoo Mohammad
Philip Mazanetz Michel
Michel Wischik Claude
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of BR112022022527A2 publication Critical patent/BR112022022527A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

COMPOSTOS DE METILTIONÍNIO PARA USO NO TRATAMENTO DE COVID-19. A presente invenção se refere a métodos de tratamento de COVID-19 em um indivíduo usando compostos de metiltionínio.
BR112022022527A 2020-05-05 2021-04-30 Compostos de metiltionínio para uso no tratamento de covid-19 BR112022022527A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2006659.3A GB202006659D0 (en) 2020-05-05 2020-05-05 Therapeutic treatments
PCT/EP2021/061481 WO2021224145A1 (en) 2020-05-05 2021-04-30 Methylthioninium compounds for use in the treatment of covid-19

Publications (1)

Publication Number Publication Date
BR112022022527A2 true BR112022022527A2 (pt) 2022-12-13

Family

ID=71080353

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022527A BR112022022527A2 (pt) 2020-05-05 2021-04-30 Compostos de metiltionínio para uso no tratamento de covid-19

Country Status (12)

Country Link
US (1) US20230165876A1 (pt)
EP (1) EP4146224A1 (pt)
JP (1) JP2023524127A (pt)
KR (1) KR20230014709A (pt)
CN (1) CN116194107A (pt)
AU (1) AU2021269001A1 (pt)
BR (1) BR112022022527A2 (pt)
CA (1) CA3181391A1 (pt)
GB (1) GB202006659D0 (pt)
MX (1) MX2022013885A (pt)
TW (1) TW202200151A (pt)
WO (1) WO2021224145A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264423A1 (en) 2005-05-20 2006-11-23 Bioenvision, Inc. Methylene Blue Therapy of Viral Disease
PT2013191E (pt) 2006-03-29 2010-10-29 Wista Lab Ltd Sais de 3,7-diamino-10h-fenotiazina e a sua utilização
US9283230B2 (en) * 2011-02-11 2016-03-15 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
KR102475825B1 (ko) 2016-07-25 2022-12-08 위스타 레보레이토리스 리미티드 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage)
EP4364801A2 (en) * 2018-07-26 2024-05-08 WisTa Laboratories Ltd. Optimised dosage of diaminophenothiazines in populations

Also Published As

Publication number Publication date
AU2021269001A1 (en) 2022-12-08
US20230165876A1 (en) 2023-06-01
EP4146224A1 (en) 2023-03-15
CN116194107A (zh) 2023-05-30
CA3181391A1 (en) 2021-11-11
KR20230014709A (ko) 2023-01-30
TW202200151A (zh) 2022-01-01
GB202006659D0 (en) 2020-06-17
JP2023524127A (ja) 2023-06-08
WO2021224145A1 (en) 2021-11-11
MX2022013885A (es) 2022-11-30

Similar Documents

Publication Publication Date Title
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
BR112021016620A2 (pt) Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
CL2013002185A1 (es) Compuestos derivados de terpenos modificados en c-17 y c3, inhibidores de la maduración del vih; compuestos intermediarios; composición farmacéutica que los comprende; su uso para tratar la infección por vih.
BR112017022323A2 (pt) método para tratar doença do enxerto contra hospedeiro, uso de um composto, e, kit.
BR112019001039A2 (pt) composição para uso no tratamento de transtorno depressivo maior
BR112015006037A2 (pt) métodos para tratamento de hcv
CO2022000481A2 (es) Inhibidores de enzimas
BR112017004589A2 (pt) composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
PE20151494A1 (es) Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
BR112019020421A8 (pt) Derivados de 2-oxo- tiazóis como inibidores de a2a e compostos para uso no tratamento de cânceres
CO2019002517A2 (es) Inhibidores de dopamina–β–hidroxilasa
EA202091676A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
BR112017025263A2 (pt) método para o tratamento de doença neurológica
BR112022000713A2 (pt) Imidazopirimidinas como inibidores de eed e o uso das mesmas
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
BR112021017661A2 (pt) Uso de compostos 8,9-di-hidrocanabidiol
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
CO2022000270A2 (es) Inhibidores de enzimas
BR112019008241A2 (pt) tratamento do prurigo nodular
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
BR112015006056A2 (pt) métodos para tratar hcv

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]